Loren Data's SAM Daily™

FBO DAILY ISSUE OF SEPTEMBER 21, 2006 FBO #1760
MODIFICATION

B -- Defining Host and HPV Gene Expression Profiles

Notice Date

9/19/2006
 

Notice Type

Modification
 

NAICS

541380 — Testing Laboratories
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-60188-NG
 

Response Due

9/21/2006
 

Archive Date

10/6/2006
 

Point of Contact

Malinda Holdcraft, Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
 

E-Mail Address

holdcram@exchange.nih.gov, rs442i@nih.gov
 

Description

This modification revises previously issued FBO notice for solicitation NCI-60188-NG. The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis in accordance with 13.106-1(b)(1), services regarding: Expanded Evaluation of Gene Expression in the Succeed Study: Defining Host and HPV Gene Expression Profiles by Specific Cervix Cell Populations and Disease Status, with the University of Wisconsin, 1525 Linden Drive, Madison WI 53706. The supplies and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13. The North American Industry Classification System code is 541380 and the business size standard is $11M. The purpose of this requisition is to provide service for optimized laser capture microdissection in cervical tissue, RNA extraction and amplification, and conduct of the Affymetrix U133 plus 2.0 human expression array chip. Services shall be provided for one year from date of award. The University of Wisconsin at Madison presently constructs an in-house HPV array chip that contains 70-mer oligonucleotide probes for all genes of all 37 sequenced mucosotropic HPV genotypes as well as a few selected host genes. The chip has been verified and optimized with various known samples including HPV-expressing keratinocyte cell lines (NIHS, W12, CaSKI), oral cancer-driven cell lines, and primary cancer tissue, detection of unintegrated HPB DNA and the ability to add additional probes as desired, such as spliced mRNA junctions. HPV chip is produced solely by the University of Wisconsin at Madison and the utilization of these assays is critical to the proposed analysis of SUCCEED specimens for host and viral expression, to expand the previous contract MQ-515642 where initial SUCCEED tissue specimens have been evaluated, it is imperative for study validity that the expansion be conducted within the same laboratory using the same assays. Under the previous contract, 72 specimens from SUCCEED (Study to Understand Cervical Cancer Early Endpoints and Determinants) were evaluated for specimen quality and both host and viral expression. Based on those analyses, it was determined that data from additional specimens would be necessary for scientifically sound and robust analyses to address our primary scientific objectives. This requirement is to continue the evaluation, so that we may increase the number of specimens for robust statistical analyses when combined with results from those specimens already evaluated under the previous contract. The expansion of this study is critical to attain a proper sample size for scientifically sound evaluation of primary study results. Handling of specimens in an identical manner as those handled under the previous contract is mandatory and essential for the scientific integrity of the project. All data elements obtained under the present contract must also be identical to the data elements obtained under the previous contract for combined analysis. The specimens under the proposed contract and with those handled in the previous contract can not be handled or evaluated differently if their results are to be combined for analyses. The same techniques must be applied to all specimens equally in order to obtain standardized and scientifically sound results across all specimens so that results can be evaluated in totality, including that of the in-house HPV array that is only developed at the University of Wisconsin. Under the previous contract, specimens were analyzed by the in-house HPV array chip that not only contains 70-mer oligonucleotide probes for all genes of all 37 sequenced mucosotropic HPV genotypes, but includes a tailored selection of specific host genes necessary for independent comparison with host array data. This chip with all 37 sequenced mucosotropic HPV genotyped and the specified host genes is unique to the University of Wisconsin and has importantly been verified and optimized with at least three HPV-expressing keratinocyte cell lines, with an oral cancer-drive cell line, and primary cancer tissue. Additionally, we required other unique attributes to the chip, including the detection of unintegrated HPV DNA within the array and the ability to add additional probes. The University of Wisconsin is the only source known to the NCI with this specific HPV chip and the ability to maintain consistency in the study. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party has the unique capabilities, resources and personnel to perform the requirement. Capability statements must be received in the contracting office by 1:00 PM EDT, on September 21, 2006. For further information please contact Malinda Holdcraft, Contract Specialist via electronic mail at holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference NCI-60188-NG.
 

Place of Performance

Address: Contractor location

Zip Code: 53706

Country: UNITED STATES
 

Record

SN01147840-W 20060921/060919220202 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |